CA2904119C - Traitement d'une insulinoresistance associee a une inactivite physique prolongee - Google Patents

Traitement d'une insulinoresistance associee a une inactivite physique prolongee Download PDF

Info

Publication number
CA2904119C
CA2904119C CA2904119A CA2904119A CA2904119C CA 2904119 C CA2904119 C CA 2904119C CA 2904119 A CA2904119 A CA 2904119A CA 2904119 A CA2904119 A CA 2904119A CA 2904119 C CA2904119 C CA 2904119C
Authority
CA
Canada
Prior art keywords
subject
hmb
physical inactivity
levels
subjects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2904119A
Other languages
English (en)
Other versions
CA2904119A1 (fr
Inventor
Menghua LUO
Suzette Pereira
Neile Edens
Gerard Davis
Susan GAWEL
Raj CHANDRAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CA2904119A1 publication Critical patent/CA2904119A1/fr
Application granted granted Critical
Publication of CA2904119C publication Critical patent/CA2904119C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des biomarqueurs d'insulinorésistance et des procédés associés d'utilisation des biomarqueurs. Les biomarqueurs peuvent être des biomarqueurs sanguins et comprendre un peptide C, une protéine 2 de liaison de facteur de croissance insulinodoïde (IGFBP-2) et une leptine. L'invention concerne également un procédé pour réduire l'effet d'une inactivité physique prolongée sur l'insulinorésistance chez un sujet affecté par une inactivité physique prolongée ou qui s'attend à expérimenter prochainement une inactivité physique prolongée.
CA2904119A 2013-03-14 2014-03-14 Traitement d'une insulinoresistance associee a une inactivite physique prolongee Active CA2904119C (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361783301P 2013-03-14 2013-03-14
US61/783,301 2013-03-14
US201361840990P 2013-06-28 2013-06-28
US61/840,990 2013-06-28
US201361866061P 2013-08-15 2013-08-15
US61/866,061 2013-08-15
PCT/US2014/027524 WO2014152606A2 (fr) 2013-03-14 2014-03-14 Traitement d'une insulinorésistance associée à une inactivité physique prolongée

Publications (2)

Publication Number Publication Date
CA2904119A1 CA2904119A1 (fr) 2014-09-25
CA2904119C true CA2904119C (fr) 2018-01-02

Family

ID=50549469

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2904119A Active CA2904119C (fr) 2013-03-14 2014-03-14 Traitement d'une insulinoresistance associee a une inactivite physique prolongee

Country Status (11)

Country Link
US (1) US9713598B2 (fr)
EP (1) EP2968236A2 (fr)
JP (1) JP2016513701A (fr)
CN (1) CN105188695A (fr)
BR (1) BR112015022997A2 (fr)
CA (1) CA2904119C (fr)
HK (1) HK1220391A1 (fr)
MX (1) MX2015012821A (fr)
PH (1) PH12015502068A1 (fr)
SG (1) SG11201507390SA (fr)
WO (1) WO2014152606A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016323779B2 (en) * 2015-09-16 2022-03-17 Metabolic Technologies, Inc. Compositions and methods of use of β-hydroxy-β-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma
CN121695115A (zh) * 2016-01-21 2026-03-20 代谢科技有限责任公司 β-羟基-β-甲基丁酸(HMB)用于调节自噬和噬脂的组合物和方法
US11406609B2 (en) 2016-01-21 2022-08-09 Metabolic Technologies, Inc. Compositions and methods of use of β-hydroxy-β-methylbutyrate (HMB) for modulating autophagy and lipophagy
EP4312594A1 (fr) * 2021-03-31 2024-02-07 Abbott Laboratories Méthodes et compositions pour améliorer la production et la sécrétion d'insuline

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6031000A (en) * 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
US20060003959A1 (en) 2004-06-10 2006-01-05 Steven Burden Methods and agents for maintaining muscle mass and for preventing muscle atrophy and biomarkers for monitoring same
US7601370B2 (en) 2004-07-28 2009-10-13 Abbott Laboratories Method for controlling body weight in estrogen-insufficient women
WO2006114775A2 (fr) * 2005-04-27 2006-11-02 Tg Biotech Traitement du syndrome de l'insulinoresistance
EP1774973A1 (fr) * 2005-10-12 2007-04-18 Nutricia N.V. Composition riche en leucine
ES2548432T3 (es) 2005-12-19 2015-10-16 Abbott Laboratories Uso de beta-hidroxi-beta-metilbutirato para modular el desequilibrio en la producción de citoquinas de tipo 1 y tipo 2
WO2007092433A2 (fr) 2006-02-06 2007-08-16 Tethys Bioscience, Inc. Marqueurs associés à l'ostéoporose et leurs méthodes d'utilisation
JP2009155336A (ja) * 2009-03-31 2009-07-16 Tsujido Chemical Corp 治療剤
RU2012105901A (ru) * 2009-07-20 2013-08-27 Нестек С.А. Способы снижения потери функционального состояния
WO2011060374A2 (fr) 2009-11-13 2011-05-19 The Johns Hopkins University Méthode, kit ou diagnostic de détection de réactifs induisant une modification de la contractilité
ES2608483T3 (es) 2009-12-18 2017-04-11 Metabolic Technologies, Inc. Método mejorado de administración de beta-hidroxi-beta-metilbutirato (HMB)
MX2012009318A (es) 2010-02-10 2012-09-07 Novartis Ag Metodos y compuestos para el crecimiento muscular.
EP2658535A1 (fr) * 2010-12-27 2013-11-06 Abbott Laboratories Méthodes permettant de faciliter la récupération musculaire après une période d'inactivité faisant appel à du bêta-hydroxy-bêta-méthylbutyrate
WO2012097064A1 (fr) * 2011-01-13 2012-07-19 Abbott Laboratories Compositions nutritionnelles et procédés pour contrôler le glucose dans le sang
MX2014000419A (es) * 2011-07-15 2014-09-22 Nusirt Sciences Inc Composicones y metodos para modular trayectorias metabolicas.
SG11201405905WA (en) 2012-03-19 2014-11-27 Abbott Lab Beta-hydroxy-beta-methylbutyric acid for improving glucose tolerance

Also Published As

Publication number Publication date
HK1220391A1 (zh) 2017-05-05
PH12015502068A1 (en) 2016-01-25
EP2968236A2 (fr) 2016-01-20
CA2904119A1 (fr) 2014-09-25
US9713598B2 (en) 2017-07-25
WO2014152606A2 (fr) 2014-09-25
BR112015022997A2 (pt) 2017-07-18
JP2016513701A (ja) 2016-05-16
CN105188695A (zh) 2015-12-23
WO2014152606A3 (fr) 2015-02-05
US20160022617A1 (en) 2016-01-28
MX2015012821A (es) 2016-05-31
SG11201507390SA (en) 2015-10-29

Similar Documents

Publication Publication Date Title
Wilcken Problems in the management of urea cycle disorders
Hamed et al. Vascular risks and complications in diabetes mellitus: the role of Helicobacter pylori infection
Santilli et al. Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus
TEKIN et al. A study of the etiology of idiopathic calcium urolithiasis in children: hypocitruria is the most important risk factor
Meyers et al. Fecal α1-antitrypsin measurement: an indicator of Crohn's disease activity
Haskell et al. Population-based plasma kinetics of an oral dose of [2H4] retinyl acetate among preschool-aged, Peruvian children
Gür Güven et al. Urolithiasis in the first year of life
US9713598B2 (en) Treatment of insulin resistance associated with prolonged physical inactivity
WO2014152610A1 (fr) Marqueurs biologiques, procédés et systèmes associés pour prévoir la perte de masse musculaire
Troncone et al. Immunologic and intestinal permeability tests as predictors of relapse during gluten challenge in childhood coeliac disease
Stagi et al. Changed bone status in human immunodeficiency virus type 1 (HIV‐1) perinatally infected children is related to low serum free IGF‐I
JP2004529363A (ja) 膵臓に基づく脂肪吸収不良障害を診断するための方法およびキット
Bell et al. Microproteinuria in children with vesicoureteric reflux
Lossy et al. A study of test dose excretion of five B complex vitamins in man
Reinahrt et al. Quantitation of Urinary Tamm-Horsfall Protein in Children with Urinary T ract Infection
US20150057350A1 (en) Fibrosis biomarkers and methods of using same
Chung et al. Influence of overweight on 24-hour urine chemistry studies and recurrent urolithiasis in children
JP3490715B2 (ja) ヘモグロビン前進性グルコシル化終末産物の検出方法
Ravaglia et al. Plasma amino acid concentrations in healthy and cognitively impaired oldest-old individuals: associations with anthropometric parameters of body composition and functional disability
EP1450859B1 (fr) Methodes et compositions permettant de diagnostiquer l'asthme
Trutin et al. AN INFANT WITH IDIOPATHIC HYPERCALCIURIA AND NEPHROLITHIASIS ASSOCIATED WITH CYP24A1 ENZYME POLYMORPHISM: A CASE REPORT.
Morán et al. Association between serum concentration of apolipoproteins AI and B with gallbladder disease
EP3397960B1 (fr) Méthode pour définir la masse du corps
Vietti et al. Gait Disturbance Secondary to Scurvy in Patients with ASD and Avoidant/Restrictive Food Intake Disorder (ARFID): Presentation of a Case Series
Fernandes et al. Follow-up of paediatric patients with celiac disease

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150903

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250916

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20251106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251110